The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
A Merrill Lynch research note to clients titled, "Diabetics scared off therapy," contains some interesting observations about what's happened to the oral diabetes drug market in the wake of the Avandia safety scare earlier this year.
Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.
Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.
GlaxoSmithKline's cervical cancer vaccine Cervarix faces a delay in winning approval in the United States, putting it further behind Merck's rival product Gardasil.
Study results show the new oral drug Tykerb from GlaxoSmithKline, combined with chemotherapy, may shrink metastatic brain tumors.
Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.
One of two top executives who lost out two months ago in the race to become chief executive of GlaxoSmithKline Plc is joining the board, while the other is to leave, Europe's biggest drugmaker said on Friday.
The popular diabetes drug marketed as Avandia may increase bone thinning, a discovery that could help explain why diabetics can have an increased risk of fractures.
Late yesterday, a bullet crossed the Dow Jones newswire saying, "FDA Warns GlaxoSmithKline on Breast-Cancer Drug Promotion." Almost immediately, my producer and I got a call from the CNBC staffer who was manning what we call our "Alerts Desk" asking us if we'd seen the news and if we could provide any context.
GlaxoSmithKline has agreed to buy privately held heart drug specialist Reliant Pharmaceuticals for $1.65 billion in cash, Europe's biggest pharmaceuticals group said on Wednesday.
It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. Last week the FDA slapped a so-called "Black Box"--the agency's most severe warning--on the Avandia label advising patients and doctors about the potential heart attack and stroke risk that's been the subject of so much controversy over the past several months.
Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa
Buying in tech stocks could lift the market again Wednesday, but Merrill Lynch earnings hang in front of the opening bell like a dark cloud. Or should we say Merrill's report of losses. The firm is scheduled to report third quarter numbers between 7:30 and 8 a.m., and analysts are forecasting a loss of $0.45 per share.
British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.
Stocks closed mixed after reversing an earlier selloff, helped by rumors circulated that the Federal Reserve would soon cut the discount rate.
Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.
GlaxoSmithKline posted a lower profit on Wednesday due to tumbling sales of its Avandia diabetes drug, generic competition and pressure on top-selling asthma treatment Advair, and said it would cut jobs to save costs.
It isn't moving the stock, but Dendreon this morning announced that it has signed up all of the patients for the big clinical trial that could lead to its prostate cancer drug, Provenge, winning Food and Drug Administration approval. The completion of enrollment was not unexpected, so that's why people aren't trading on the news.
U.S. regulators said warnings about the risk of sudden hearing loss linked to popular drugs for impotence, including Viagra, Cialis and Levitra, would be added to the drugs' labels.